HC Wainwright Issues Negative Outlook for Evotec Earnings

Evotec SE (NASDAQ:EVO - Free Report) - Analysts at HC Wainwright cut their Q1 2025 earnings per share estimates for shares of Evotec in a research note issued on Monday, April 21st. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of ($0.05) per share for the quarter, down from their prior estimate of ($0.01). The consensus estimate for Evotec's current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Evotec's Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.20) EPS and FY2026 earnings at $0.00 EPS.

Separately, Deutsche Bank Aktiengesellschaft raised shares of Evotec from a "sell" rating to a "hold" rating in a research report on Thursday.

Evotec Trading Up 0.5 %

NASDAQ:EVO traded up $0.02 on Wednesday, reaching $4.24. 25,120 shares of the stock traded hands, compared to its average volume of 131,844. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.99 and a current ratio of 2.09. Evotec has a 1-year low of $2.84 and a 1-year high of $5.68. The company's 50 day moving average is $3.64 and its 200-day moving average is $4.10.

Institutional Investors Weigh In On Evotec

Institutional investors and hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets purchased a new stake in shares of Evotec in the fourth quarter valued at about $27,000. CSS LLC IL bought a new position in shares of Evotec during the 4th quarter worth approximately $50,000. Bank of America Corp DE grew its holdings in shares of Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock valued at $53,000 after acquiring an additional 9,289 shares in the last quarter. Lighthouse Investment Partners LLC bought a new stake in Evotec during the fourth quarter worth $166,000. Finally, DCF Advisers LLC grew its stake in Evotec by 5.9% in the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock valued at $956,000 after purchasing an additional 12,816 shares during the period. 5.81% of the stock is owned by hedge funds and other institutional investors.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.